Sugi Predict

Sugi Predict / Compounds / SCHEMBL1706301

SCHEMBL1706301

SCHEMBL1706301

Cc1cc2ccccc2nc1Nc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ MAPT P10636 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ HTT P42858 1/20 0.48
▸ EPHX2 P34913 1/20 0.48
▸ CTSC P53634 1/20 0.47
▸ DHODH Q02127 2/20 0.45
▸ DHFR P00374 1/20 0.44
▸ IDH1 O75874 4/20 0.43
▸ ABL1 P00519 2/20 0.43
▸ BCR P11274 2/20 0.43
▸ CHRNA7 P36544 1/20 0.42
▸ TRPM8 Q7Z2W7 1/20 0.42
▸ TTBK1 Q5TCY1 1/20 0.41
▸ TTBK2 Q6IQ55 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ IGF1R P08069 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL13517466 0.99 SMN1; SMN2 (0.50) SMN1; SMN2MAPTMEN1NPC1RAB9A
SCHEMBL25854283 0.90 MAPT (0.45) SMN1; SMN2MAPTMEN1NPC1RAB9A
SCHEMBL1702525 0.87 IGF1R (0.53) MAPTMEN1KMT2AHTTEPHX2
SCHEMBL1702147 0.85 MAPT (0.46) SMN1; SMN2MAPTMEN1NPC1RAB9A
SCHEMBL22116277 0.84 CTSC (0.59) SMN1; SMN2MAPTMEN1NPC1RAB9A
SCHEMBL1706249 0.83 MAPT (0.67) SMN1; SMN2MAPTMEN1NPC1RAB9A
SCHEMBL17432138 0.83 MAPT (0.61) SMN1; SMN2MAPTMEN1NPC1RAB9A
SCHEMBL17208353 0.83 TRPA1 (0.42) SMN1; SMN2MAPTMEN1NPC1RAB9A
SCHEMBL1706188 0.79 EPHX2 (0.48) SMN1; SMN2MAPTMEN1RAB9AKMT2A
SCHEMBL22134947 0.79 KDM1A (0.49) SMN1; SMN2MAPTMEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440546-B1 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA ABIVAX (FR) 2022-12-28 — — EP claimed
EP-2440547-B1 New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects ABIVAX (FR) 2022-11-30 — — EP claimed
EP-3517534-A1 COMPOUNDS USEFUL FOR TREATING CANCER ABIVAX (FR) 2019-07-31 — — EP claimed
US-10017498-B2 Compounds useful for treating AIDS ABIVAX (FR) 2018-07-10 — — US claimed
US-9827237-B2 Compounds useful for treating diseases caused by retroviruses ABIVAX (FR) 2017-11-28 — — US claimed
US-20160151348-A1 COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES ABIVAX (FR) 2016-06-02 — — US claimed
EP-3016656-A1 BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES ABIVAX (FR) 2016-05-11 — — EP claimed
CN-105530938-A Compounds for the treatment of diseases caused by retroviruses ABIVAX 2016-04-27 — — CN claimed
US-20150307478-A1 COMPOUNDS USEFUL FOR TREATING AIDS UNIVERSITE DE MONTPELLIER (FR) 2015-10-29 — — US claimed
CN-104945378-A Compounds for the treatment of premature aging and especially premature aging ABIVAX 2015-09-30 — — CN claimed
WO-2015001518-A1 BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES SPLICOS (FR) 2015-01-08 — — WO claimed
US-20140080831-A1 COMPOUNDS USEFUL FOR TREATING CANCER CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) 2014-03-20 — — US claimed
US-20120329796-A1 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA SOCIETE SPLICOS (FR) 2012-12-27 — — US claimed
US-20120283265-A1 COMPOUNDS USEFUL FOR TREATING AIDS SOCIETE SPLICOS (FR) 2012-11-08 — — US claimed
US-20120277230-A1 COMPOUNDS USEFUL FOR TREATING CANCER SOCIETE SPLICOS (FR) 2012-11-01 — — US claimed
CN-102625804-A Compounds for the treatment of AIDS SPLICOS SOC 2012-08-01 — — CN claimed
CN-102596935-A Compounds for the treatment of premature aging and especially premature aging SPLICOS SOC 2012-07-18 — — CN claimed
CN-102574835-A Compounds for the treatment of cancer SPLICOS SOC 2012-07-11 — — CN claimed
EP-2440545-A2 COMPOUNDS USEFUL FOR TREATING CANCER Société Splicos (FR) 2012-04-18 — — EP claimed
WO-2010143168-A2 COMPOUNDS USEFUL FOR TREATING CANCER SOCIÉTÉ SPLICOS (FR) 2010-12-16 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10017498-B2 Compounds useful for treating AIDS NR1H3, NR1H2, NR1H4 SMN1; SMN2 4057/4885MAPT 4010/4885MEN1 3719/4885
US-20120283265-A1 COMPOUNDS USEFUL FOR TREATING AIDS CBR1, CNR1, CBR3 SMN1; SMN2 4559/4885MAPT 4329/4885MEN1 3647/4885
US-20120277230-A1 COMPOUNDS USEFUL FOR TREATING CANCER CBR1, CBR3, NCOR1 SMN1; SMN2 4495/4885MAPT 4736/4885MEN1 1925/4885
US-20120329796-A1 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA NR2C2, NCOR2, NR4A2 SMN1; SMN2 1391/4885MAPT 4162/4885MEN1 3042/4885
US-20150307478-A1 COMPOUNDS USEFUL FOR TREATING AIDS NR1H3, NR1H2, NR1H4 SMN1; SMN2 4057/4885MAPT 4010/4885MEN1 3719/4885
US-20160151348-A1 COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES RCOR1, CBR1, RCOR3 SMN1; SMN2 2094/4885MAPT 3658/4885MEN1 2704/4885
US-20140080831-A1 COMPOUNDS USEFUL FOR TREATING CANCER NR1H4, NR1H3, NCOR1 SMN1; SMN2 4475/4885MAPT 4707/4885MEN1 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.